Skip to content

effect of ozone on low back pain.

Comparison of transforaminal ozone injection Vs triamcinolon infilteration on chronic radicular low back pain.

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
IRCT
Registry ID
IRCT201610177984N26
Enrollment
64
Registered
2017-02-12
Start date
2016-01-01
Completion date
Unknown
Last updated
2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

low Back Pain. low Back Pain with Sciatica

Interventions

Intervention 1: (10ml of 30micro/ml ozone +5ml bupivacaine 0.2%)per root. Intervention 2: 20mg triamcinolone +5ml bupivacaine 0.2% per root will inject.
Treatment - Surgery
(10ml of 30micro/ml ozone +5ml bupivacaine 0.2%)per root.
20mg triamcinolone +5ml bupivacaine 0.2% per root will inject

Sponsors

Vice chansellor for research, Iran University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 70 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria including: Radicular LBP that persistent more than 6 weeks; Root impression due to disc bulging or foraminal narrowing that confirmable in MRI; The patient age must be between 18 -70 yr old; Physical status level I to II according to ASA physical status classification system. Valid, written consent to participate in study must be obtained; Pain score must be more than 4 according to numerical rating scale(NRS)tool; Lack of pain relieve to medication and physical therapy; Three or less nerve root must be involved. Exclusion criteria including: If coagulopathy to exist; presence of systemic or zone of needle entry point infection; Severe anatomical distortion(for example scoliosis); presence history of back surgery or device implantation; Severe psychotic disorder is co-exist; history of allergy to local anesthetics is positive; if progressive deficiency or motor deficit to exist; If malignancy, pregnancy, or history of substance abuse, HIV and /or chronic hepatitis marker positive to exist; If acute trauma; or cauda equina syndrome to exist.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Pain. Timepoint: befor itervention will started,and the end of weeks two and four months three and six. Method of measurement: Nnmrical Rating Scale tool of pain.;Chronic pain biomarker, TNFalpha in serum. Timepoint: befor itervention will started,and the end of month two. Method of measurement: Venous Blood sample.;Root Impression in MRI. Timepoint: Before intervention and the end of second month. Method of measurement: MRI imagine.

Secondary

MeasureTime frame
Disability. Timepoint: befor intervention will start,the end of weeks two and four,months three and six. Method of measurement: Oswestry Disability Questionnaire.;Labratory data, BUN, Cr, Bs. Timepoint: befor intervention will start,the end of weeks two and four,months three and six. Method of measurement: Venous blood sample.;Dermatomal pain distribiotion,posetive SLR(and degree of), revres SLR. Timepoint: before intervention will start,the end of weeks two and four,month three and six. Method of measurement: Pain that induced with physical examination and it's distribution,degree of range of motion that induced pain,.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactFarnad Imani

Hemmat Highway Iran University of Medical Sciences

farnadimani@yahoo.com+98 21 6435 2326

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026